お気に入りに追加
製品詳細
Synonyms
CD8 alpha & beta, CD8A & CD8B
Source
Biotinylated Cynomolgus CD8A&CD8B Heterodimer Protein, His,Avitag&Tag Free (CDA-C82W3) is expressed from human 293 cells (HEK293). It contains AA Ser 22 - Asp 182 & Leu 22 - Pro 170 (Accession # XP_065382910.1 & XP_005575417.1).
Predicted N-terminus: Ser 22 & Leu 22
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
Biotinylated Cynomolgus CD8A&CD8B Heterodimer Protein, His,Avitag&Tag Free, produced by co-expression of CD8 alpha and CD8 beta, has a calculated MW of 25.4 kDa (CD8 alpha) and 21.1 kDa (CD8 beta). Subunit CD8 alpha is fused with a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™) and subunit CD8 beta contains no tag at the C-terminus. The protein migrates as 30-32 kDa and 33-35 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
The protein is designed as a heterodimer.
Labeling
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
Protein Ratio
Passed as determined by the SABA assay / HABA assay / binding ELISA.
Purity
>95% as determined by SDS-PAGE.
>95% as determined by SEC-MALS.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Shipping and Storage
This product is shipped at ambient temperature.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
お客様はこちらも閲覧
データ表示
SDS-PAGE
Biotinylated Cynomolgus CD8A&CD8B Heterodimer Protein, His,Avitag&Tag Free on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).
SEC-MALS
The purity of Biotinylated Cynomolgus CD8A&CD8B Heterodimer Protein, His,Avitag&Tag Free (Cat. No. CDA-C82W3) is more than 95% and the molecular weight of this protein is around 50-75 kDa verified by SEC-MALS.
Report
Bioactivity-ELISA
Immobilized Human Anti-CD8 alpha Antibody, Human IgG1 at 1 μg/mL (100 μL/well) can bind Biotinylated Cynomolgus CD8A&CD8B Heterodimer Protein, His,Avitag&Tag Free (Cat. No. CDA-C82W3) with a linear range of 0.002-0.063 μg/mL (QC tested).
Protocol
ユーザーレビュー コメントを投稿
よくある質問
- product
Can lyophilized proteins remain stable during room-temperature shipping or temporary room-temperature exposure?
In general, lyophilized proteins remain stable during room-temperature shipping or temporary exposure to room-temperature conditions.
Many ACROBiosystems recombinant proteins are supplied in lyophilized (freeze-dried) form. The lyophilization process effectively removes moisture from the product, helping reduce degradation-related reactions and improve protein stability during transportation and storage.
To evaluate the stability of lyophilized proteins under normal temperature conditions, ACROBiosystems conducted a stability study on 11 representative lyophilized protein products at 37°C. The study demonstrated that these proteins maintained good quality stability after storage at 37°C for approximately 20 days. Based on these validation results, temporary room-temperature exposure during shipping or handling is generally not expected to have a significant impact on product quality or downstream application performance.
To ensure optimal long-term stability, products should be stored according to the storage conditions specified in the product Certificate of Analysis (COA) upon receipt.
Supporting Document
バックグランド
最新の進展
医薬品開発の進捗- 英語名：
T-cell surface glycoprotein CD8 beta chain
- カテゴリ：
- 市販の医薬品数：
0 詳細
- 治験医薬品数：
0 詳細
- 最新の開発ステージ：
Preclinical
お問い合わせ
メールアドレス
order.jp@acrobiosystems.com
お問い合わせ
グローバル：+1 800-810-0816(Toll Free)
医薬品候補ライセンス
